Ovarian Cancer News & Features
Researchers explored the effectiveness of wearing frozen gloves and socks before and after treatment with PLD to prevent or manage hand-foot syndrome in patients with ovarian cancer.
Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients
1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival compared to those treated with surgery and chemotherapy alone. 2. No difference in grade 3 or 4 adverse side effects were observed between HIPEC and non-HIPEC treated 
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average) Study Rundown: Females with BRCA1 mutations in their germline 
Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.
Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.
Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.
Ovarian Cancer Clinical Trials
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|